Trials / Completed
CompletedNCT00952445
A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- InteKrin Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T0903131 Besylate | Once daily, oral |
| DRUG | Placebo | Once daily, oral |
Timeline
- Start date
- 2003-12-01
- Completion
- 2004-06-01
- First posted
- 2009-08-06
- Last updated
- 2022-10-19
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00952445. Inclusion in this directory is not an endorsement.